Plain-English summary
Court affirms that FDA can deny authorization for new tobacco products and allows limited judicial review
The Court affirmed the Fifth Circuit, holding that the FDA may deny authorization for new tobacco products under the Tobacco Control Act and that petitioners’ challenges to certain procedural aspects must proceed in lower courts. The judgment is affirmed and remanded.
Why this matters
The ruling clarifies how far the FDA’s authority extends over the approval and denial of new tobacco and vaping products and confirms that companies must follow the agency’s authorization process. It affects regulatory control over the sale and marketing of e-cigarettes and other nicotine products, public-health oversight, and the ability of manufacturers to obtain or challenge authorizations in court.
Who may feel it
- E-cigarette and vaping product manufacturers and distributors
- Tobacco product companies seeking FDA authorization
- Public health regulators and state health agencies
- Retailers who sell vaping and other tobacco products
- Consumers of vaping and tobacco products
Key questions
- Does the Family Smoking Prevention and Tobacco Control Act require FDA authorization before introducing new tobacco products into interstate commerce?